MedTrace Logo

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

NCT01692301 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 454

Last updated 2016-05-04

Study results available
· View outcomes & findings →

Summary

The study examined the efficacy of LCZ696 in comparison to the ARB olmesartan on Central Aortic Systolic Blood Pressure (CASP) and other measures of central hemodynamics and arterial stiffness in elderly patients with an elevated systolic blood pressure (SBP) and widened pulse pressure (PP).

Conditions

Interventions

DRUG

LCZ696

200 mg tablet

DRUG

Olmesartan

20 mg and 40 mg capsules

DRUG

LCZ696 matching placebo

LCZ696 Matching Placebo tablet

DRUG

Olmesartan matching placebo

Olmesartan matching placebo capsule

DRUG

amlodipine

amlodipine 2.5 mg or 5 mg tablets

DRUG

hydrochlorothiazide

hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States
  • Argentina
  • Colombia
  • France
  • Germany
  • Greece
  • Italy
  • Japan
  • Russia
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01692301 on ClinicalTrials.gov